Barclays Capital Reiterates Overweight on Ariad Pharmaceutical (ARIA)

By admin | 6 years ago

Ariad Pharmaceutical (NASDAQ: ARIA)‘s stock had its “overweight” rating restated by analysts at Barclays Capital (NYSE: BCS) in a research report issued to clients and investors on Tuesday.

A number of other firms have also recently commented on ARIA. Analysts at Summer Street raised their price target on shares of Ariad Pharmaceutical to $21.00 in a research note to investors on Monday, May 14th. Finally, analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Ariad Pharmaceutical to $18.00 in a research note to investors on Thursday, May 10th.

Ariad Pharmaceutical traded up 3.02% on Tuesday, hitting $16.69. Ariad Pharmaceutical has a 1-year low of $7.55 and a 1-year high of $17.60. The company’s market cap is $2.766 billion.

Ariad Pharmaceutical last released its earnings data on Wednesday, May 9th. The company reported ($0.35) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.12. Ariad Pharmaceutical’s revenue was up 33.3% compared to the same quarter last year. Analysts expect that Ariad Pharmaceutical will post $-0.31 EPS next quarter.

ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level.

About the author